AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01591902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Description: Daily 2 mg subcutaneous injections of tesamorelin
Study NCT01591902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: 3.0 mL vials
Study NCT00124579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
Study NCT00124579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
Study NCT00124579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 100 mg/d PO days 1-21 every 21 days
Study NCT00197561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
Study NCT00197561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
Study NCT01953731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.~In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
Study NCT01953731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
Study NCT01098058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT plus treatment as usual
Description: 16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
Study NCT01098058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
Study NCT03080402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Perturbation Training
Description: The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
Study NCT00004317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: See arm descriptions
Study NCT03474952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (RIPC)
Description: remote ischemic preconditioning consists of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion using pneumatic cuff applied to upper arm
Study NCT03474952 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham-RIPC
Description: ischemia pressure less than 10 mmHg (sham-RIPC)
Study NCT02416167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FYU-981
Study NCT01796678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine
Study NCT01796678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline or Sugar pill was given as placebo
Study NCT02416167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01244516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: galyfilcon A, BC 8.30
Description: galyfilcon A, BC 8.30 soft contact lens
Study NCT01244516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B, BC 8.60
Description: lotrafilcon B, BC 8.60 soft contact lens
Study NCT01244516 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: comfilcon A, BC 8.60
Description: comfilcon A, BC 8.60 soft contact lens
Study NCT02660047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
Study NCT00004317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: See arm descriptions
Study NCT00004317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spiramycin
Description: Spiramycin is administered before the fetal diagnosis is made.
Study NCT00004317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadiazine
Description: See arm descriptions
Study NCT01182077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: Oral
Study NCT01182077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral
Study NCT01723891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surfolase capsule
Study NCT01723891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-002-01
Study NCT03123120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: 12 weeks treatment
Study NCT03123120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks treatment
Study NCT02353312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kuvan
Description: Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
Study NCT02353312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
Study NCT02417454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProbioStick
Description: One sachet daily, without or without meals (3 x 10\^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)
Study NCT02187939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.
Description: The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
Study NCT02187939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.
Description: The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
Study NCT02263118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uni-directional SMS
Description: Exposure to breastfeeding promoting SMSs
Study NCT02263118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feature phone
Description: Participants were given a feature phone.
Study NCT02417454 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sachet daily, without or without meals (0 CFU per sachet)
Study NCT02263118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual communities
Description: Exposure to virtual community communication via SMS
Study NCT02263118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid setup
Description: Exposure to virtual community and access to communications with health professional via SMS
Study NCT02437175 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ENDO 1/ENDO 2
Description: NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
Study NCT02437175 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
Study NCT00745459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPO-11
Description: 20 mL NPO-11
Study NCT01062100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nuclear breast imaging using MBI Gamma camera
Description: nuclear breast imaging using MBI Gamma camera in addition to MRI
Study NCT03713515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ALTA
Description: The study will involve each site starting with the usual care phase, followed by a period of 6 months during which practice facilitators will conduct the pre-implementation evaluation (e.g., workflow analysis, environmental scan), refine the practice facilitation strategies that will be used in the implementation phase, and train staff in the Advancing Medication Adherence for Latinos with Hypertension through a Team-based Care Approach (ALTA) intervention model. ALTA is an efficacious systems-level intervention designed to help patients improve their ability to take their high blood pressure medications and control their blood pressure. Practices and the Project ALTA team will work together to implement the ALTA model into routine care to improve blood pressure control and medication adherence in Latinx patients.
Study NCT02439801 — intervention group
Intervention type: PROCEDURE
Intervention: PEEP 0
Description: 0 cmH2O positive end expiratory pressure
Study NCT02439801 — intervention group
Intervention type: PROCEDURE
Intervention: PEEP 5
Description: 5 cmH2O positive end expiratory pressure
Study NCT02439801 — intervention group
Intervention type: PROCEDURE
Intervention: PEEP 8
Description: 8 cmH2O positive end expiratory pressure
Study NCT03506776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Education and Thermometer Group
Description: The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
Study NCT03506776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Only Group
Description: The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
Study NCT04473339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRS+HIPEC
Description: Patients will undergo only CRS, HIPEC and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS.
Study NCT04112693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)
Description: In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies intended for histopathological analysis will be analyzed in FFOCT before histopathological analysis. The FFOCT analysis take place for the patient inclued after than 10 november 2020.~The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse.
Study NCT04473339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CRS alone
Description: Patients will undergo only CRS and IVCT.Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS and then followed by maintenance therapy.
Study NCT00956709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaïne 0,5 %
Description: 20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
Study NCT00956709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaïne 0,5 %
Description: 20mL de ropivacaïne 0,5 %
Study NCT02549144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fat/cholesterol diet
Description: The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.
Study NCT02549144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat/cholesterol diet
Description: The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day
Study NCT02304094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: the steroid group shall receive a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
Study NCT02304094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual manipulation
Description: the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
Study NCT04417491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Real dry needling will be conducted according to the fast-in and fast-out principle. The intervention will be applied until a total of four local twitch responses will be elicited
Study NCT03969979 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shear wave elastography
Description: shear wave elastogrophy will be performed
Study NCT03914209 — intervention group
Intervention type: OTHER
Intervention: EHL clotting factor
Description: This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
Study NCT01473589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered by SC injection
Study NCT01473589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection
Study NCT01473589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium supplementation
Description: Administered orally
Study NCT04417491 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Needling
Description: Sham dry needling with be conducted with a sham needle device. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating a sensation on the patient
Study NCT03660956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
Study NCT01473589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Description: Administered orally
Study NCT03660956 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back counselling
Description: Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
Study NCT01473589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D supplementation
Description: Administered orally
Study NCT01473589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Administered orally
Study NCT03074916 — intervention group
Intervention type: DEVICE
Intervention: DIP arthroplasty or arthrodesis
Description: Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
Study NCT03660956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back counselling
Description: Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
Study NCT01462188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate stenting
Description: Primary coronary stenting
Study NCT01462188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed stenting
Description: Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
Study NCT03212586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1902607
Description: Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
Study NCT03212586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
Study NCT02488044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB1102
Description: modified human arginase I
Study NCT04650828 — intervention group
Intervention type: DRUG
Intervention: TDF
Description: TDF combined with telbivudine (LDT) for 12 months
Study NCT00390572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Specialty Consultation
Description: The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.